Literature DB >> 6376219

Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.

W J Andrews, B Vasquez, M Nagulesparan, I Klimes, J Foley, R Unger, G M Reaven.   

Abstract

The effects of rigorous insulin treatment on insulin action (insulin clamp) and secretion (plasma insulin response to glucose) were studied in 13 obese patients with non-insulin-dependent diabetes mellitus (NIDDM). Improvements were documented in fasting (P less than 0.0001) and postprandial (P less than 0.0001) plasma glucose concentrations, insulin secretion after oral glucose (P less than 0.001), and insulin action (P less than 0.005) after 30 days of therapy. Mean integrated plasma insulin response to glucose increased 2.5-fold after insulin therapy, but this improvement varied considerably from patient to patient. Insulin action also increased with insulin treatment and the resulting values were no longer significantly different from a weight- and age-matched group of subjects with normal glucose tolerance. However, there was considerable patient-to-patient variation in the degree to which insulin action was enhanced. The insulin-induced improvements in glucose tolerance persisted for at least 2 wk after insulin withdrawal, and were associated with continued increased insulin secretion and insulin action. In conclusion, control of hyperglycemia for 1 mo led to improvements in both insulin secretion and action in a series of obese patients with NIDDM that persisted for at least 2 wk after cessation of therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376219     DOI: 10.2337/diab.33.7.634

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  29 in total

1.  Differential regulation of two distinct glucose transporter species expressed in 3T3-L1 adipocytes: effect of chronic insulin and tolbutamide treatment.

Authors:  K M Tordjman; K A Leingang; D E James; M M Mueckler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus.

Authors:  W T Garvey; T P Huecksteadt; S Matthaei; J M Olefsky
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

3.  Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents.

Authors:  M Krempf; T Godeau; S Ranganathan; P Blanchard; P Ritz; B Charbonnel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Effects of prolonged glucose stimulation on pancreatic beta cells: from increased sensitivity to desensitization.

Authors:  F Purrello; A M Rabuazzo; M Anello; G Patanè
Journal:  Acta Diabetol       Date:  1996-12       Impact factor: 4.280

Review 5.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

Review 6.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 7.  When to use insulin in the maturity onset diabetic.

Authors:  R B Tattersall; A R Scott
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

Review 8.  The insulin receptor concept and its relation to the treatment of diabetes.

Authors:  G M Ward
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

9.  Insulin resistance and mechanical dysfunction in hearts of Wistar rats with streptozotocin-induced non-insulin-dependent diabetes mellitus.

Authors:  S W Schaffer; G L Wilson
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

10.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.